BeOne Medicines Ltd. (ONC)
374.08
+22.60
(+6.43%)
USD |
NASDAQ |
Oct 15, 16:00
372.57
-1.51
(-0.40%)
After-Hours: 05:58
BeOne Medicines Research and Development Expense (Quarterly) : 593.46M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 593.46M |
| March 31, 2026 | 521.31M |
| December 31, 2025 | 599.87M |
| September 30, 2025 | 505.42M |
| June 30, 2025 | 510.26M |
| March 31, 2025 | 462.96M |
| December 31, 2024 | 518.00M |
| September 30, 2024 | 453.22M |
| June 30, 2024 | 430.71M |
| March 31, 2024 | 436.53M |
| December 31, 2023 | 473.12M |
| September 30, 2023 | 434.02M |
| June 30, 2023 | 401.46M |
| March 31, 2023 | 389.56M |
| December 31, 2022 | 428.98M |
| September 30, 2022 | 426.36M |
| June 30, 2022 | 361.50M |
| March 31, 2022 | 374.85M |
| December 31, 2021 | 418.98M |
| September 30, 2021 | 352.41M |
| June 30, 2021 | 344.87M |
| March 31, 2021 | 311.28M |
| Date | Value |
|---|---|
| December 31, 2020 | 347.90M |
| September 30, 2020 | 340.91M |
| June 30, 2020 | 278.29M |
| March 31, 2020 | 296.84M |
| December 31, 2019 | 276.11M |
| September 30, 2019 | 233.28M |
| June 30, 2019 | 225.40M |
| March 31, 2019 | 175.27M |
| December 31, 2018 | 254.75M |
| September 30, 2018 | 145.38M |
| June 30, 2018 | 162.15M |
| March 31, 2018 | 107.72M |
| December 31, 2017 | 89.64M |
| September 30, 2017 | 86.42M |
| June 30, 2017 | 46.70M |
| March 31, 2017 | 41.91M |
| December 31, 2016 | 28.46M |
| September 30, 2016 | 29.60M |
| June 30, 2016 | 20.62M |
| March 31, 2016 | 17.44M |
| December 31, 2015 | 28.10M |
| September 30, 2015 | 30.15M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 13.25M |
| CRISPR Therapeutics AG | 64.95M |
| Idorsia Ltd. | 31.45M |